Out of (Assay) Range

Bioanalytical lab services occupy a quietly essential position in drug development: they build and run the reagents, assays, and markers through which a sponsor learns whether a molecule is behaving in a living system the way the data say it should. The global market for these services was valued at approximately $4.8 billion in 2024 and is projected to reach somewhere between $9 and $11 billion by the early 2030s, depending on the forecast you trust, with CAGRs consistently estimated in the 8–10% range.¹ The structural drivers are well understood: a swelling biologics pipeline, an accelerating shift toward outsourcing by pharma and biotech sponsors, and the growing complexity of the molecules themselves — ADCs, bispecific antibodies, cell and gene therapies, RNA-based therapeutics — each of which demands new assay approaches that most sponsors lack the internal capability to build and validate. The complicating reality is that the technical demands of this work are rising faster than the industry’s ability to staff and instrument for them.

What owners are navigating right now

The industry’s tailwinds are real, but operators are absorbing a set of compounding pressures that make strong revenue growth feel less like a reward than a test. Across conversations with practitioners, a few themes recur consistently.

• A mid-sized specialty CRO with a strong small-molecule PK business finds its longtime pharma clients increasingly submitting large-molecule and biologic programs. The lab has the instrumentation (LC-MS/MS, a couple of Gyrolabs) but the scientists who can develop and validate ligand-binding assays for novel biologics are hard to find and harder to keep. The team is stretched, turnaround times are slipping, and client conversations that used to be straightforward are now involving a lot of careful expectation-setting about timelines. Revenue is up; margin and morale are both under pressure.

• A founder-owned bioanalytical lab with deep regulatory credibility — no major findings across two decades of FDA audits — is wrestling with what ICH M10 implementation actually looks like in practice. The guideline harmonized method validation requirements across FDA, EMA, and other major jurisdictions starting in 2022–2023, but areas like cross-validation criteria and endogenous analyte bioanalysis remain contested in their interpretation. The founder is spending meaningful time in industry working groups and rewriting SOPs, which is valuable work that no one is billing for.²

• A well-regarded independent lab that built its reputation on bioequivalence work for generics sponsors is watching that segment evolve. Biosimilar development — which requires demonstrating therapeutic equivalence for complex large-molecule reference products — is growing as a share of the BE pipeline. The work is meaningfully more complex than small-molecule BE, requires different instrumentation and expertise, and commands different pricing. The lab is navigating whether to invest in capabilities they don’t yet fully have or refer the work to larger players and risk the relationship.³

The platform question

The most interesting strategic tension in bioanalytical services right now is between depth and breadth. Larger providers — Eurofins, LabCorp Drug Development, Charles River, ICON to name a few — are building platform-scale capacity to serve sponsors across every modality and every phase of development. That’s genuinely useful for a Pfizer or AstraZeneca that wants a single vendor relationship across a global approval pathway. But for the founder-owned lab with real scientific depth in a specific area (say, cell-based assays for immunogenicity, or radiolabeled ADME studies, or high-parameter flow cytometry) the question is whether that depth is enough to anchor a durable client base or whether it becomes a capability that the large players simply acquire when they need it.

The answer probably depends on how regulated the work is and how hard it is to replicate. A lab that has spent years building validated assay libraries for a specific therapeutic area, and whose scientists have built trusted relationships with the clinical teams at their sponsor clients, is not trivially displaced. The data it generates supports IND and BLA filings; the regulatory credibility that comes from a clean audit history has real value that doesn’t transfer easily in an acquisition. Whether that translates into pricing power is a separate question, one that some operators we’ve observed are tentatively beginning to press.

What we’re watching

Bioanalytical labs (and the tool and equipment infrastructure that help them run) sit at the intersection of several things Watershed finds genuinely interesting: technically demanding work that is hard to commoditize, a regulatory environment that reinforces the value of institutional experience, and a capital structure (instrument-heavy but services-oriented) that doesn’t necessarily require constant reinvention to stay relevant. The large-molecule transition is real and it’s pressuring operators in ways that create interesting dynamics around positioning, pricing, and investment timing.

Questions? Comments? Critiques? Always happy to compare notes with anyone else deeply involved and invested. Feel free to reach out anytime at david@watershedholdco.com.